D. McDonald

发表

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

David C. Smith, J. Taube, M. Atkins, 2012, The New England journal of medicine.

Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice

J. Pidala, D. McDonald, Chen Liu, 2015, PloS one.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).

L. Sequist, S. Gettinger, J. Wigginton, 2012 .

Controlling T Cell Differentiation and Acute Graft-versus-Host Disease through T-bet Is Critical for the Development of

C. Anasetti, D. McDonald, Chen Liu, 2014 .

A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.

J. Wolchok, B. Fox, F. Hodi, 2014 .

A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.

J. Wolchok, B. Fox, F. Hodi, 2013 .

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

David C. Smith, T. Choueiri, M. Atkins, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T-bet Is Critical for the Development of Acute Graft-versus-Host Disease through Controlling T Cell Differentiation and Function

C. Anasetti, D. McDonald, Chen Liu, 2012, The Journal of Immunology.

Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).

J. Sosman, F. Hodi, M. Sznol, 2012 .

Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).

David C. Smith, T. Choueiri, M. Atkins, 2012 .

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma.

B. Nathwani, A. Tulpule, J. Kolitz, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody.

A. Gupta, S. Agrawal, G. Kollia, 2012 .

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors

J. Wolchok, F. Hodi, G. Gibney, 2016 .

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

T-bet Is Critical for the Development of Acute Graft-versus-Host Disease through Controlling T Cell Differentiation and Function

C. Anasetti, D. McDonald, Chen Liu, 2015, The Journal of Immunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.